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AbstrAct
Introduction We investigated risk of coronary heart 
disease and heart failure in phenotypes of obstructive 
airway disease.
Methods Among 91 692 participants in the Copenhagen 
General Population Study, 42 058 individuals were 
classified with no respiratory disease, and 11 988 
individuals had different phenotypes of obstructive 
airways disease: asthma with early onset or late- onset, 
chronic obstructive pulmonary disease (COPD) with forced 
expiratory volume in one second (FEV1) above or below 
50% of predicted value (%p) or asthma- COPD overlap 
(ACO).
results During a mean follow- up of 5.7 years we 
registered 3584 admissions for coronary heart disease 
and 1590 admissions for heart failure. Multivariable Cox 
regression analyses of time to first admission were used 
with a two- sided p value of 0.05 as significance level. 
Compared with no respiratory disease the highest risks of 
coronary heart disease and heart failure were observed 
in ACO with late- onset asthma and FEV1 <50% p, HR=2.2 
(95% CI 1.6 to 3.0), and HR=2.9 (95% CI 2.0 to 4.3), 
respectively. In COPD with FEV1 above 50% p the HRs were 
1.3 (95% CI 1.2 to 1.5) for coronary heart disease and 1.9 
(95% CI 1.6 to 2.3) for heart failure. Asthma associated 
with increased risks of coronary heart disease and heart 
failure, however, in asthma without allergy the HR was 
1.1 (95% CI 0.7 to 1.6) for coronary heart disease while 
individuals with allergy had an HR of 1.4 (95% CI 1.1 to 
1.6).
conclusions Risks of coronary heart disease and heart 
failure were increased in asthma, COPD and ACO. In 
asthma, the risk of coronary heart disease depended on 
presence of allergy. We suggest that cardiovascular risk 
factors should be assessed systematically in individuals 
with obstructive airway disease with the potential to 
facilitate targeted treatments.
bAckground
Asthma and chronic obstructive pulmo-
nary disease (COPD) are prevalent 
chronic inflammatory airway diseases and 
an increased risk of cardiovascular comor-
bidity has been described in both.1 2 Recent 
systematic reviews suggest that the risk 
of being diagnosed with coronary heart 
disease or heart failure is approximately 
twofold higher in individuals with asthma 
and even higher in COPD.3–5
In patients with asthma, observed asso-
ciations with cardiovascular disease are 
poorly understood, inconsistent,6–8 and 
recently it has been proposed that the risk 
could depend on age of asthma onset.9–11 
Furthermore, studies have indicated that 
allergy associates with risk of cardiovas-
cular disease.12 Since allergy is associ-
ated with asthma13 this could influence 
observed associations between asthma and 
risk of cardiovascular comorbidity.
Other studies have shown an association 
between COPD and risk of cardiovascular 
disease. However, a recent systematic liter-
ature review points to inconsistencies in 
these associations with lack of adjustment 
for important and well- characterised clinical 
characteristics, and a paucity of significant 
prospective studies.4
Key messages
 ► Do different phenotypes of obstructive airway dis-
ease associate with increased risk of coronary heart 
disease and heart failure?
 ► Several population- based studies have shown an 
association between chronic obstructive pulmo-
nary disease (COPD) and cardiovascular disease, 
however, most studies lack adjustment for import-
ant clinical characteristics and prospective designs. 
Similarly, previously observed associations between 
asthma and cardiovascular disease are poorly un-
derstood, and recently it has been proposed that 
these associations could depend on age of asthma 
onset or presence of allergy. Furthermore, there are 
to date few studies investigating the association 
between asthma- COPD overlap and cardiovascular 
disease.
 ► Obstructive airway disease phenotypes increase risk 
of cardiovascular disease, but could depend on aller-
gy presence in individuals with asthma.
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Recently, asthma- COPD overlap (ACO) has been 
acknowledged as a clinical entity,14 that is, individuals 
with persistent airflow limitation and features usually 
associated with both COPD and asthma,15 but only few 
studies have focused on cardiovascular comorbidity 
in individuals with ACO.16 These studies have mostly 
been cross- sectional and based on registry data without 
comprehensive information on clinical and lifestyle char-
acteristics16–18 but significant associations between ACO 
and both coronary heart disease and heart failure have 
been reported in retrospective study designs.19
We hypothesised that obstructive airway disease 
phenotypes, asthma, COPD and ACO are prospec-
tively associated with risk of coronary heart disease 
and heart failure.
Methods
Participants
In the present study, we analysed data from The Copen-
hagen General Population Study. Written informed 
consent was obtained from all participants. The Copen-
hagen General Population Study is a prospective epide-
miological study that has recruited more than 100 000 
individuals representative of the general population and 
collected genotypical and phenotypical data of relevance 
to a wide range of health- related problems.20 Recruit-
ment began in 2003 (response rate 45%), and a follow- up 
examination of all individuals was initiated in 2014 and 
is still ongoing. In the present study we had access to 
participants examined in the first examination from 2003 
to 2014 and therefore the follow- up examination (the 
second round of the Copenhagen General Population 
Study) is not included in the present study. All partici-
pants completed a comprehensive questionnaire and 
underwent a physical examination including spirometry 
at recruitment. Only prebronchodilator measurements 
were available. Predicted values were calculated using 
internally derived reference values based on a subsample 
of healthy asymptomatic never- smokers, as reported 
earlier.21
Airway disease phenotypes
Among 91 692 participants aged above 40 years with 
spirometry, 2867 (3.1%) had missing data on at least one 
of the variables necessary for the stratification described 
below. Among the remaining participants, we identi-
fied 54 046 individuals defined by one of eight groups 
of different phenotypes of airway disease, based on the 
information obtained in the questionnaires and results 
of spirometry, and a reference group consisting of partic-
ipants with no respiratory disease:
 ► No respiratory disease: individuals with forced expiratory 
volume in one second (FEV1)/forced vital capacity 
(FVC) ≥0.70, no self- reported asthma, no prior admis-
sions for asthma and COPD, and ≤10 pack- years of 
tobacco smoking.
 ► Asthma with early onset: current self- reported asthma 
with onset before 40 years of age, ≤10 pack- years of 
tobacco smoking and FEV1/FVC≥0.70.
 ► Asthma with late- onset: current self- reported asthma 
with onset after 40 years of age, ≤10 pack- years of 
tobacco smoking and FEV1/FVC≥0.70.
 ► COPD with FEV1≥50% of predicted value: FEV1/
FVC<0.70 with >10 pack- years of tobacco smoking, 
no self- reported asthma and FEV1 ≥50% of predicted 
value
 ► COPD with FEV1<50% of predicted value: FEV1/
FVC<0.70 with >10 pack- years of tobacco smoking, 
no self- reported asthma and FEV1<50% of predicted 
value.
 ► ACO with early onset asthma and FEV1≥50% of predicted 
value: current self- reported asthma with onset before 
40 years of age, FEV1/FVC<0.70 and FEV1≥50% of 
predicted value. There were no criteria regarding 
smoking for assignment into this group.
 ► ACO with late- onset asthma and FEV1≥50% of predicted 
value: current self- reported asthma with onset after 
40 years of age, FEV1/FVC<0.70 and FEV1≥50% of 
predicted value. There were no criteria regarding 
smoking for assignment into this group.
 ► ACO with early onset asthma and FEV1<50% of predicted 
value: current self- reported asthma with onset before 
40 years of age, FEV1/FVC<0.70 and FEV1<50% of 
predicted value. There were no criteria regarding 
smoking for assignment into this group.
 ► ACO with late- onset asthma and FEV1<50% of predicted 
value: current self- reported asthma with onset after 
40 years of age, FEV1/FVC<0.70 and FEV1<50% of 
predicted value. There were no criteria regarding 
smoking for assignment into this group.
Individuals with missing data were excluded. In 
the study population of 91 692 individuals, only 
3% had missing data on either smoking, body mass 
index, hypertension, family history of cardiovascular 
disease, diabetes, total cholesterol or physical activity 
in leisure time, hence imputation of missing data was 
not performed.
hospitalisations for coronary heart disease and heart failure
Data on hospitalisations were available from the national 
Danish Patient Registry,22 23 until November 2014. The 
national Danish Patient Registry was established in 1977 
and provides complete nationwide registry data without 
loss to follow- up. Data are available on permission for 
research purposes from 1977 and forward and the cardi-
ovascular diagnoses have a high specificity and positive 
predictive value.24 25 Denmark used the International 
Classification of Diseases (ICD)-8 until 1994 and here-
after shifted directly to ICD-10. Participants with previous 
admissions for COPD (ICD-8: 491–492 and ICD-10: J41–
J44) and asthma (ICD-8: 493 and ICD-10: J45–J46) were 
removed from the reference group of no respiratory 
disease. We recorded hospital admissions for coronary 
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heart disease (ICD-8: 410–414 and ICD-10: I20–I25) and 
heart failure (ICD-8: 427.09–427.11 and ICD-10: I50), and 
in our main analysis individuals with previous admissions 
of coronary heart disease and heart failure were included 
in the prospective analysis, however, we also performed 
a sensitivity analysis excluding individuals with previous 
cardiovascular admissions from our analysis, as described 
below.
Patient and public involvement
Patients were not involved in the development of the 
research question or outcome measure, nor in the design 
of the study, recruitment to or conduct of the study. 
Results are not disseminated to the study participants 
and patient advisers were not involved.
Licence for publication
The corresponding author has the right to grant on behalf 
of all authors and does grant on behalf of all authors, 
an exclusive licence (or non- exclusive for government 
employees) on a worldwide basis to the BMJ Publishing 
Group to permit this article to be published in BJO and 
any other BMJPGL
products and sublicences such use and exploit all 
subsidiary rights, as set out in our licence (http:// group. 
bmj. com/ products/ journals/ instructions- for- authors/ 
licence- forms).
statistical analysis
For demographics, continuous variables and categor-
ical variables were compared using analysis of variance 
and χ2 tests as appropriate. The Kaplan- Meier estimator 
was used to estimate the percentage of events during 
follow- up after the initial examination, accounting for 
censoring of data. Hence, percentages presented are 
100% minus the Kaplan- Meier estimate of being event- 
free. Kaplan- Meier curves were included to describe the 
clinical prognosis for groups of individuals with obstruc-
tive airway disease phenotypes, thereby indicating which 
patients are at increased risk. To estimate the confounder 
adjusted risks of hospital admissions we used a Cox regres-
sion model. Time since examination was the underlying 
timescale and all Cox models were adjusted for age. In 
a base model, age and gender were included as covari-
ates, and in a full multivariable model we also included 
established cardiovascular risk factors: family history of 
cardiovascular disease, smoking, body mass index, hyper-
tension, diabetes mellitus, total cholesterol levels and 
physical activity in leisure time26 (details of all variables 
are provided in the online supplementary table S1). In 
our analysis, a two- sided p value less than 0.05 was consid-
ered significant. The assumption of proportionality in 
the Cox regression models were tested with the Lin, Wei 
and Ying Score process test by visual examination of plots 
of cumulative martingale residuals, and no violations of 
the model assumptions were found.27 No adjustments 
for multiple comparisons were made. All analyses were 
performed with R V.3.2.0 (R Foundation for Statistical 
Computing, Vienna, Austria).28
Sensitivity analyses
Asthma with or without allergy
Previous studies have indicated that there is an 
association between allergy and risk of cardiovas-
cular disease.12 Due to the rather low numbers of 
participants in our main analysis in some of the 
phenotype subgroups, we disregarded age of onset 
in our asthma definition and divided asthma into 
two other groups: asthma with or without allergy. 
Presence of allergy was defined by answering yes to 
the question ‘Do foods, medicine, grass, flowers, 
animal hair or other factors cause asthma, hay fever 
or eczema in you?’. In the reference group (‘No 
respiratory disease’) individuals reporting presence 
of allergy were excluded explaining a smaller refer-
ence group.
Furthermore, we also did a subgroup sensitivity analysis 
by analysing the association between presence of allergy 
compared with no presence of allergy in the ‘No respira-
tory disease’ subgroup, and prospective risk of coronary 
heart disease and heart failure.
Age of asthma onset
Early onset asthma and late- onset asthma were defined 
based on a previous study using 40 years of age as the 
cut point.29 However, this choice could be discussed, 
and we did a second sensitivity analysis with 20 years 
of age as the cut point defining early onset versus late- 
onset asthma.
No history of admissions with coronary heart disease or heart 
failure
In our third sensitivity analysis, acknowledging the pres-
ence of coronary heart disease and heart failure in some 
individuals with obstructive airway disease at baseline, we 
excluded these individuals from our study population 
and repeated our analysis.
Adjusting for pack-years
Smoking cessation is a strong predictor of cardiovas-
cular disease30 and cumulated tobacco consumption 
measured in pack- years was used to define some of our 
airway disease phenotype subgroups. Therefore, we 
initially adjusted our main analysis for smoking status 
as current/former/never. However, in our fourth and 
final sensitivity analysis acknowledging that smoking 
is a possible strong confounder we adjusted our main 
analysis for cumulated smoking exposure calculated 
in pack- years, as this variable could have a finer reso-
lution and provide better confounder control than 
smoking status.
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resuLts
characteristics of participants with different phenotypes of 
airway disease
The distribution of the 54 046 participants and their char-
acteristics are shown in the table 1. There were 11 988 
individuals with any airway disease and 1901 of these 
were classified as having ACO. Individuals with ACO 
constituted 2.1% of all participants, 15.9% of those in the 
airway disease phenotype groups and 19.3% of all those 
with airflow limitation.
General characteristics
As shown in the table, severity of lung function impair-
ment in individuals with COPD and ACO was related 
to presence of dyspnoea (ie, mMRC ≥2) whereas a 
high frequency of previous respiratory infections was 
particularly present in ACO with FEV1<50% p, regard-
less of age of asthma onset. Prevalence of treatment 
with medication for respiratory disease was highest in 
participants with ACO, followed by those with asthma, 
and then those with COPD and FEV1<50% p, whereas 
only 6% of those with COPD and FEV1≥50% p were on 
medical treatment. Current smoking was most preva-
lent in those with COPD. Individuals with asthma and 
those with ACO with early onset asthma more often 
reported having experienced asthma, hay fever or 
eczema in childhood.
Cardiovascular disease
The prevalence of cardiovascular disease was highest in 
participants with FEV1<50% p in both COPD and ACO 
as shown in the table. There was a trend towards higher 
blood pressure and a higher prevalence of diabetes 
mellitus in COPD and ACO with FEV1<50% p, and more 
individuals with these obstructive airway disease pheno-
types reported a low physical activity level in leisure time. 
Furthermore, family history of cardiovascular disease, 
total cholesterol, and HDL cholesterol levels seemed 
largely similar across different phenotypes of airway 
disease.
hospitalisations for coronary heart disease and heart failure
During an average follow- up of 5.7 years (maximum: 
11.0 years), 3584 admissions for coronary heart 
disease and 1590 admissions for heart failure were 
recorded.
Figure 1 shows Kaplan- Meier curves with regard to 
admissions for coronary heart disease while figure 2 
shows heart failure. These unadjusted analyses illus-
trate the increased risks of coronary heart disease and 
heart failure in real life groups of individuals with 
different phenotypes of obstructive airway disease.
Figure 3 shows adjusted HRs for hospitalisations 
due to coronary heart disease in the left panel and 
heart failure in the right panel. In full multivariable 
models, early onset asthma did not associate with 
coronary heart disease with an HR of 1.2 (95% CI 
0.9 to 1.6, p=0.13) but was associated with heart 
failure HR=2.2 (95% CI 1.4 to 3.4, p<0.001). Late- 
onset asthma was associated with both coronary heart 
disease and heart failure, HR=1.4 (95% CI 1.1 to 1.7, 
p=0.01) and HR=1.5 (95% CI 1.1 to 2.2, p=0.02), 
respectively.
The highest risks of coronary heart disease and heart 
failure were observed in COPD with FEV1<50% p and 
in ACO with late- onset asthma and FEV1<50% p, and 
the HR was 1.8 (95% CI 1.4 to 2.3, p<0.001) and 2.2 
(95% CI 1.6 to 3.0, p<0.001), respectively, for coronary 
heart disease, and 2.9 (95% CI 2.2 to 3.9, p<0.001) 
and 2.9 (95% CI 2.0 to 4.3, p<0.001), respectively, for 
heart failure, compared with no respiratory disease. 
Interestingly, COPD with FEV≥50% p also associated 
with coronary heart disease as well as heart failure 
even when adjusting for established cardiovascular 
risk factors, HR=1.3 (95% CI 1.2 to 1.5, p<0.001) and 
HR=1.9 (95% CI 1.6 to 2.3, p<0.001), respectively.
sensitivity analyses
Asthma with or without allergy
Online supplementary table S2 shows characteristics 
of individuals with asthma with or without allergy and 
ACO with or without allergy. As shown in figure 4, 
asthma without allergy did not associate with risk of 
coronary heart disease, HR=1.1 (95% CI 0.7 to 1.6, 
p=0.73), while asthma with presence of allergy was 
significantly associated and the HR was 1.4 (95% 
CI 1.1 to 1.6, p=0.002) for coronary heart disease 
compared with no respiratory disease. Similarly, ACO 
with Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) 1+2 COPD without allergy did not 
associate with risk of coronary heart disease, HR=1.1 
(95% CI 0.8 to 1.6, p=0.41) while ACO with GOLD 
1+2 COPD and allergy had an HR of 1.4 (95% CI 1.1 
to 1.7, p<0.001) for coronary heart disease compared 
with no respiratory disease. Asthma with or without 
allergy and ACO with or without allergy associated 
significantly with risk of heart failure.
Furthermore, there were no associations between 
allergy and coronary heart disease (multivariable 
adjusted HR=1.03 (95% CI 0.93 to 1.13, p=0.60)) 
nor heart failure (multivariable adjusted HR=0.94 
(95% CI 0.79 to 1.12, p=0.51)) in the ‘No respiratory 
disease’ subgroup.
Asthma age of onset
In our second sensitivity analysis, defining early versus 
late asthma onset by using 20 years as the age cut point, 
we observed only minor changes and most HRs and p 
values were largely unchanged compared with our main 
analyses, as shown in online supplementary figure S1. 
Importantly, though, using this cut point, asthma with 
early onset was significantly associated with risk of coro-
nary heart disease, HR=1.5 (95% CI 1.0 to 2.2, p=0.03).
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No history of admissions with coronary heart disease or heart 
failure
Excluding individuals with previous admissions of coro-
nary heart disease or heart failure from our study popula-
tion, we observed similar results as in our main analyses. 
However, statistical power was reduced by the somewhat 
smaller study population and fewer events recorded 
during follow- up, as shown in online supplementary 
figure S2. However, late- onset asthma was not statistically 
associated with heart failure, HR=1.5 (95% CI 1.0 to 2.3) 
while early onset asthma remained associated with an HR 
of 2.3 (95% CI 1.4 to 3.7).
Adjusting for pack-years
After adjustment for pack- years, we observed similar esti-
mates between obstructive airway disease phenotypes 
and prospective risk of coronary heart disease and heart 
failure as shown in online supplementary figure S3.
dIscussIon
In this large prospective study of the general popula-
tion we observed that risks of coronary heart disease and 
heart failure were increased in COPD, even in mild- to- 
moderate disease. We also observed a similar increased 
risk in individuals with ACO with observed associations 
largely explained by severity of lung function impair-
ment. Asthma also associated with risks of coronary heart 
disease and heart failure, with increased risk of coronary 
heart disease only in individuals who reported presence of 
allergy. We suggest that cardiovascular risk factors should 
be assessed systematically in obstructive airway disease 
with the potential to facilitate targeted treatments.
The burden of cardiovascular comorbidity in obstructive 
airway disease is increasingly acknowledged, and there is 
a need of identifying which patients are at increased risk31 
to facilitate optimal treatment and prevention. To our 
knowledge, this is the first large prospective population- 
based study showing that individuals with ACO have an 
increased risk of coronary heart disease and heart failure, 
and that this risk is of similar magnitude, or perhaps even 
slightly higher, than the risk observed in individuals with 
COPD. Recently, we have observed a poor survival in 
individuals with ACO in another Copenhagen cohort, 
The Copenhagen City Heart Study,29 and therefore the 
present study suggests that cardiovascular comorbidity is 
not a major part of the explanation for the poorer prog-
nosis observed in ACO compared with COPD. The preva-
lence of ACO among those with airflow limitation in the 
present study was approximately 19%, which is in line 
with the prevalence reported in other cohorts.16 17 29 32 33 
Our definition of ACO is based on objectively verified 
airflow limitation and self- reported asthma and our main 
findings of a higher risk of cardiovascular events in ACO 
are in line with findings of van Boven et al, although these 
investigators used a register- based diagnosis in their main 
analyses.16
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Figure 1 Kaplan- Meier curves comparing risk of coronary heart disease for different phenotypes of obstructive airway 
disease in the Copenhagen General Population Study. (A) Asthma with early onset or late- onset versus no respiratory 
disease. (B) COPD with FEV1<50%, COPD with FEV1≥50%, versus no respiratory disease. (C) ACO with late- onset asthma 
and FEV1≥50%, ACO with early onset asthma and FEV1≥50%, COPD with FEV1≥50%, vs no respiratory disease. (D) ACO 
with late- onset asthma and FEV1<50%, ACO with early onset asthma and FEV1<50%, COPD with FEV1<50%, versus no 
respiratory disease. ACO, asthma- COPD overlap; CHD, coronary heart disease; COPD, chronic obstructive pulmonary 
disease; FEV1, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Figure 2 Kaplan- Meier curves comparing risk of heart failure for different phenotypes of obstructive airway disease in the 
Copenhagen General Population Study. (A) Asthma with early onset or late- onset versus no respiratory disease. (B) COPD 
and FEV1<50%, COPD and FEV1≥50%, versus no respiratory disease. (C) ACO with late- onset asthma and FEV1≥50%, 
ACO with early onset asthma and FEV1≥50%, COPD with FEV1≥50%, versus no respiratory disease. D) ACO with late- onset 
asthma and FEV1<50%, ACO with early onset asthma and FEV1<50%, COPD with FEV1<50%, versus no respiratory disease. 
ACO, asthma- COPD overlap; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; 
GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Ageing in itself is a common risk factor to both obstruc-
tive airway disease and cardiovascular disease. However, 
in a recent study of ACO using the Copenhagen City 
Heart Study, we reported that age of asthma onset signifi-
cantly influenced lung function decline and survival.29 
Our present findings suggest that the age of asthma onset 
in ACO does not seem to play a major role with regard 
to future risk of cardiovascular comorbidity, which is 
somewhat surprising as previous research has indicated 
that early onset asthma and late- onset asthma could 
represent different pathological processes. However, in 
line with such a hypothesis, our main asthma analysis 
suggested that an increased risk of coronary heart disease 
might only be present in individuals with late- onset 
asthma. Similar results were observed in the Wisconsin 
Sleep Cohort9 and among women in the Atherosclerosis 
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Figure 3 Risk of hospitalisations for coronary heart disease or heart failure in the Copenhagen General Population Study, 
by eight phenotypes of airway disease with no respiratory disease as reference. Percentages are Kaplan- Meier estimates. 
Individuals with asthma are divided by early onset versus late- onset using 40 years of age as cut point. Left part shows 
coronary heart disease and right part shows heart failure. Top- down: base model or multivariable model (‘Age and sex 
adjusted model‘ or ‘Multivariable adjusted model’). Left to right: the number of participants included (‘No. of Participants’), 
number of events recorded during follow- up (“Events No.’), HR from Cox- regression analyses with 95% CIs (“Hazard Ratio 
(95% CI)"). Online supplementary table S1 shows details of variables included in multivariable modelling. ACO, asthma- COPD 
overlap; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease.
Risk in Communities Study.10 Importantly, in our sensi-
tivity analysis using 20 years as the cut point, both early 
onset and late- onset asthma associated with risk of coro-
nary heart disease. Thus, the lack of association with 
early onset asthma in our main analysis could depend 
on the choice of age cut point. Furthermore, limitations 
regarding our asthma definition should be acknowl-
edged. Both heavy smoking history and airflow limitation 
were exclusion criteria in this group, thereby excluding 
individuals with a major cardiovascular risk factor or with 
obstructive lung function impairment.3 7 34 35 We thus 
recognise that our results may not apply to individuals 
with asthma and presence of airflow limitation, although 
the majority of individuals with asthma in the general 
population do not show presence of obstruction on 
spirometry.
Previous studies have indicated that presence of allergy 
could be associated with increased risk of cardiovas-
cular disease.12 Therefore, we did a sensitivity analysis 
dividing asthmatic individuals by presence of allergy. In 
this analysis, we observed that only asthma with pres-
ence of allergy associated significantly with the risk of 
coronary heart disease. A possible explanation could be 
cellular pathways such as mast cell release linking allergy 
in asthma with coronary heart disease.36 The hypothesis 
of inflammatory pathways as a possible common mecha-
nism is compatible with at recent finding of an increased 
risk only present in individuals with active asthma37 and 
also in line with observed associations between atopic 
dermatitis and myocardial infarction.38 Furthermore, 
the observed association between presence of allergy 
in asthma and coronary heart disease could be depen-
dent on the late- phase reaction and chronic allergic 
inflammation involving mediators such as transforming 
growth factor α,39 a cytokine that has been associated 
with coronary heart disease.40 However, many complex 
mechanisms and mediators are involved in chronic 
inflammation in allergic asthma,39 and future studies are 
needed to investigate whether there could be particular 
inflammatory links between presence of allergy in asthma 
and cardiovascular comorbidity since our subgroup sensi-
tivity analysis showed no association between presence of 
allergy without presence of asthma and prospective risk 
of cardiovascular disease.
As expected, we observed that diabetes and hyperten-
sion were strongly associated with the prospective risk of 
Bibliotek. Protected by copyright.
 o
n
 M
ay 6, 2020 at Kobenhavns Universitets
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2019-000470 on 3 February 2020. Downloaded from 
Ingebrigtsen TS, et al. BMJ Open Resp Res 2020;7:e000470. doi:10.1136/bmjresp-2019-000470 9
Open access
Figure 4 Risk of hospitalisations for coronary heart disease or heart failure in the Copenhagen General Population Study, 
by eight phenotypes of airway disease with no respiratory disease as reference. Percentages are Kaplan- Meier estimates. 
Individuals with asthma are divided by presence of allergy. Left part shows coronary heart disease and right part shows heart 
failure. Top- down: base model or multivariable model (‘Age and sex adjusted model’ or ‘Multivariable adjusted model’). Left 
to right: the number of participants included (‘No. of Participants’), number of events recorded during follow- up (‘Events No.’), 
HR from Cox- regression analyses with 95% CIs (‘Hazard Ratio (95% CI)’). Online supplementary table S1 shows details of 
variables included in multivariable modelling. ACO, asthma- COPD overlap; COPD, chronic obstructive pulmonary disease; 
CVD, cardiovascular disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
cardiovascular disease. These risk factors can be easily 
assessed at regular pulmonary examinations in an ambu-
latory setting by measuring glycated haemoglobin and 
blood pressure in other to facilitate targeted treatment. 
Our analyses also showed reduction in risk of coronary 
heart disease and heart failure associated with increased 
physical activity in leisure time, also when adjusting for 
several other important covariates. Considering that 
many previous studies have corroborated the importance 
of pulmonary rehabilitation in COPD, physical activity 
seems particularly important in patients with presence of 
both obstructive airway disease and comorbid cardiovas-
cular disease.
In addition, while increased body mass index, as 
expected, associated with increased risk of both coro-
nary heart disease and heart failure, previous research 
has shown that an increased body mass index is, in fact, 
associated with a lower risk of exacerbations in COPD.41 
This seems like a paradox as several studies have shown 
a strong association between increased risk of exacer-
bations in COPD and increased risk of cardiovascular 
events.42 We therefore also call for future studies of 
associations between body mass index, weight changes, 
and body composition and risk of exacerbations in 
individuals with obstructive airway disease and cardiovas-
cular comorbidity.
Our study seems to corroborate and supplement 
previous findings on the strong association between 
COPD, disease severity assessed by lung function impair-
ment, and future risk of coronary heart disease and 
heart failure.4 5 A major strength of our study was inclu-
sion of important clinical respiratory and cardiovas-
cular characteristics. After adjusting for established risk 
factors, we observed that even mild- to- moderate COPD 
was associated with coronary heart disease and heart 
failure. Severity of FEV1 impairment seemed important 
in our study, thus, individuals with FEV1 below 50% of 
predicted had a higher risk than those with FEV1 above 
50% p. A potential limitation is that our spirometries are 
prebronchodilator only. However, we believe that our 
findings support the notion that severity of lung function 
impairment plays the most important role in the risk of 
hospitalisations with coronary heart disease and heart 
failure in COPD. These results are in line with a previous 
study from the Copenhagen City Heart Study,43 and also 
in line with a study using the UK- based General Practice 
Research Database, where the investigators used COPD 
treatment as a proxy for disease severity and observed a 
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higher risk among those patients with COPD with most 
severe disease.44
Most individuals with COPD have a history of smoking 
and therefore, we included pack- years in our definition 
of COPD phenotype. This explains why smoking was a 
weakly associated variable in multivariable modelling. 
We are aware of the fact that the way we defined our 
subgroups of airway disease phenotypes may significantly 
affect our findings and interpretation such as exclusion of 
individuals with light smoking COPD and heavy smoking 
asthma. However, our classification used both elements 
from the Global Initiative for Asthma and GOLD docu-
ments, and also elements commonly employed to define 
inclusion criteria for drug trials in asthma and COPD.45 46
It should also be acknowledged that we lack further 
characterisation of types of airway inflammatory process 
in our individuals with different phenotypes of obstructive 
airway disease. Furthermore, as another possible limita-
tion, we only had access to information on self- reported 
asthma, and a physician- based diagnosis would likely 
be more reliable. Nevertheless, the use of self- reported 
asthma is well established for identification of asthma in 
population- based settings,47 48 as well as reported age of 
asthma onset.49
Strengths to the present study include the high number 
of enrolled participants and a complete follow- up in 
nationwide registries of diagnoses with a high speci-
ficity.24 25 We also consider the quite comprehensive 
information on both established cardiovascular and respi-
ratory risk factors and an objectively verified presence of 
airflow limitation an important advantage that allows new 
clinical information on the associations between obstruc-
tive airway disease phenotypes and prospective risk of 
coronary heart disease and heart failure.
Despite our findings, we acknowledge that whether 
obstructive airway disease phenotypes should be consid-
ered as genuine cardiovascular risk factors is still a matter 
of dispute. Recently, a large randomised trial of treat-
ment with inhaled corticosteroids and long- acting β2- 
agonists, the SUMMIT Study, aiming at reducing risk of 
cardiovascular mortality in individuals with COPD, failed 
to show any effect.50 Considering the importance of low 
lung function as a major risk factor both for cardiovas-
cular disease and mortality, and considering that the 
SUMMIT Study did not show an effect of inhaled mainte-
nance medications on mortality in subjects with COPD at 
increased cardiovascular risk, we suggest that cardiovas-
cular as well as metabolic concomitant diseases should be 
not only carefully searched for in subjects with impaired 
lung function, but also appropriately treated with cardio-
vascular and metabolic agents. All together, we therefore 
suggest that, presence of asthma, COPD and ACO should 
lead to an increased focus on established cardiovascular 
risk factors in this population and result in relevant inter-
ventions if indicated.
In conclusion, risks of coronary heart disease and 
heart failure were increased in COPD, even in mild- to- 
moderate disease. We also observed similar increased risks 
in individuals with ACO, that seemed largely explained 
by the severity of lung function impairment. Asthma also 
associated with risks of coronary heart disease and heart 
failure, with an increased risk of coronary heart disease 
only present in individuals who also reported presence of 
allergy. We suggest that cardiovascular risk factors should 
be assessed systematically in obstructive airway disease 
with the potential to facilitate targeted treatments.
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